CLINICAL_TRIALS
trial_result
· 2019-04-25
Clinical Trial Update: Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis [Phase 2]
Summary
Phase 2 trial of BAF312 (likely on symptomatic improvement in polymyositis and dermatomyositis) was terminated with posted results in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Polymyositis, Dermatomyositis | Phase 2 | Status: TERMINATED | Results posted: 2019-04-25